Navitas Life Sciences

Phase I Double Blind Safety, Tolerability and PK Evaluation of a COVID-19 Therapy in Healthy Volunteers

Our clients, Daewoong Pharmaceutical and Mankind Pharma, needed help with the expeditious and efficient conduct of a Phase I Generic drug trial to evaluate the safety and tolerability of the anti-parasitic drug Niclosamide in the treatment of COVID-19. The drug, delivered as an intramuscular depot, was found to be efficacious against SARSCoV-2 in pre-clinical studies. As this is a novel route of administration, the company needed to apply for a New Drug Application and were seeking an end-to-end clinical trials partner.

Please complete the form to download the Case Study and learn how we successfully delivered the trial.

Please complete form to download PDF
First Name
Last Name
Business Email
Company
Job Title
Country
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2021 Navitas Life Sciences | A TAKE Solutions Enterprise  
Privacy Policy EU-US & Swiss-US Privacy Shield Policy